SCHEMBL1775264

SCHEMBL1775264

CC(C)c1cccc2c1c1c(c[n+]2[O-])nc2n1CCOC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.36
ALDH1A1 P00352 2/20 0.36
TP53 P04637 6/20 0.34
MAPT P10636 5/20 0.34
MAPK1 P28482 4/20 0.34
LMNA P02545 3/20 0.34
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32
TSHR P16473 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
KDM4E B2RXH2 1/20 0.30
CYP1A2 P05177 1/20 0.30
GLA P06280 1/20 0.30
CYP3A4 P08684 1/20 0.30
GAA P10253 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
HPGD P15428 1/20 0.30
CASP1 P29466 1/20 0.30
CASP7 P55210 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4705810 0.77 ALDH1A1 (0.36) POLBALDH1A1TP53MAPTMAPK1
SCHEMBL4705375 0.73 GRM5 (0.33) MAPK1LMNAKDM4E
SCHEMBL2241078 0.72 ALDH1A1 (0.35) POLBALDH1A1TP53MAPTMAPK1
SCHEMBL10123166 0.69 POLB (0.37) POLBALDH1A1MAPTLMNANPC1
SCHEMBL4707643 0.62 POLB (0.35) POLBALDH1A1TP53MAPTMAPK1
SCHEMBL24089113 0.62 POLB (0.39) POLBALDH1A1TP53MAPTMAPK1
SCHEMBL11721926 0.61 POLB (0.57) POLBALDH1A1TP53MAPTMAPK1
SCHEMBL4707031 0.59 LMNA (0.38) POLBALDH1A1TP53MAPTMAPK1
SCHEMBL4710518 0.59 POLB (0.34) POLBALDH1A1TP53MAPTMAPK1
SCHEMBL4702114 0.59 ACHE (0.38) POLBALDH1A1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207162-B2 Chiral fused [1,2]imidazo[4,5-c] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-06-26 US disclosed
US-20110207725-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY 2011-08-25 US disclosed
US-7943609-B2 Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides 3M INNOVATIVE PROPRERTIES COMPANY (US) 2011-05-17 US disclosed
US-20080269192-A1 Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269192-A1 Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds IFNAR1, IFNG, IL4 POLB 2378/4885ALDH1A1 1323/4885TP53 339/4885
US-20110207725-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS IFNAR1, IFNG, IL4 POLB 2378/4885ALDH1A1 1323/4885TP53 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.